Controlled trial of a thymic hormone extract (Thymostimulin) in ‘autoimmune’ chronic active hepatitis

J E HEGARTY, K T NOURI ARIA, A L W F EDDLESTON, AND ROGER WILLIAMS

From the Liver Unit, King’s College Hospital and Medical School, Denmark Hill, London

SUMMARY A randomised controlled trial of thymic hormone extracts (Thymostimulin) (1 mg/kg/day for seven days; 1 mg/kg/weekly thereafter) was undertaken in 30 patients (21 women, nine men) with treated, apparently inactive ‘autoimmune’ chronic active hepatitis during withdrawal of maintenance corticosteroid and azathioprine therapy. Reactivation of disease occurred in 26 patients (86%) during or after treatment withdrawal and was as frequent in the Thymostimulin treated (11 of 13; 84%) and untreated (15 of 17; 88%; p>0·05) groups. Reactivation of disease was accompanied by a severe defect in concanavalin A induced suppressor cell activity, the magnitude of which was similar in the Thymostimulin treated and untreated groups (mean % suppression = 16·4 and 3·2 respectively; p>0·05 vs 84·4 in control subjects). Further studies assessing the optimal dose, duration of treatment, and mode of administration are required to establish a therapeutic role for thymic hormone extracts in ‘autoimmune’ chronic active hepatitis.

Chronic active hepatitis of unknown aetiology occurs predominantly in women, often with florid signs of hepatocellular failure, associated autoimmune disease, and marked derangement of liver function. Hyperglobulinaemia primarily involving an increase in immunoglobulin G,1 and the presence of specific2 and non-specific3 autoantibodies are the most striking immunological abnormalities and indicate a disturbance in the immunoregulatory mechanisms controlling antibody production. Antigen specific and non-specific suppressor T lymphocytes are considered to play a major regulatory role in controlling B cell immunoglobulin production4 5 and a defect in suppressor T cell function has been implicated in the pathogenesis of human6 7 and experimentally induced autoimmune disease,8 including chronic active hepatitis.9

Several studies in vitro have shown that thymic hormone extracts stimulate human suppressor T cell activity10 11 and inhibit immunoglobulin production12 13 suggesting a possible role for their use in the treatment of autoimmune disease. The present study was designed to evaluate the effect of Thymostimulin (a calf thymic extract) in preventing clinical deterioration in a group of patients with autoimmune chronic active hepatitis, in apparently complete remission for prolonged periods, in whom conventional treatment was being withdrawn. Concurrent studies were performed to assess suppressor cell function in patients before and during treatment with Thymostimulin.

Methods

PATIENTS

Thirty patients (21 women, nine men, aged 20–69 years) satisfied internationally agreed criteria for chronic active hepatitis.14 The sera of all patients contained autoantibodies (smooth muscle and/or antinuclear factor) in titres greater than 1/40 at some time during the course of their illness and all were negative for hepatitis B surface antigen and antibody by radioimmunoassay (Austria II and Ausab respectively, Abbott Laboratories, Basingstoke, UK). None had been exposed to known hepatotoxic drugs or transfused with blood or blood products. Duration of disease ranged from three to six years and remission from two to four years as
defined by an absence of symptoms, serum amino- 
transferase (AST) concentrations within the normal 
range (<40 IU/l) on at least four consecutive six 
monthly estimations, and liver histology showing 
mild portal lymphocytic infiltration in the absence of 
piecemeal necrosis. All patients were receiving 
prednisolone (5–10 mg) and azathioprine (75–100 
mg) daily as maintenance treatment. In two patients 
on one previous occasion, withdrawal of treatment 
had resulted in biochemical relapse (AST>240 IU/l) 
of disease. The study was approved by the ethical 
committee of King’s College Hospital and informed 
consent was obtained from all subjects.

Thymostimulin was kindly supplied by Serono 
Laboratories (UK) Welwyn Garden City, 
Herts. The method of extraction and purification 
has been previously described.15 Briefly, ammonium 
acetate extraction of minced calf thymuses is 
followed by two precipitation steps with ammonium 
sulphate. The precipitate from the second step is 
subjected to ultrafiltration and then purified on 
Sepharose G25 and G50. The resulting extract 
contains a mixture of polypeptides with molecular 
weights lower than12 000, with two main bands on 
polyacrylamide gel electrophoresis. Standardisation 
of the activity of the extract is performed by 
comparing it with a standard preparation of Thymo-
stimulin in a bioassay using induction of rosette 
forming cells in guinea pig spleen preparations.16

The patients were randomised to receive intra-
muscular Thymostimulin 1 mg/kg/day for one week, 
and 1 mg/kg/week thereafter (13 patients), or no 
therapy (17 patients) at the beginning of treatment 
withdrawal. Azathioprine was discontinued and 
prednisolone simultaneously reduced by 2 mg and 
by a further 2 mg at two weekly intervals. Serum 
concentrations of AST, bilirubin, alkaline 
phosphatase, immunoglobulins, and autoantibody 
titres were monitored at two weekly intervals. A 
fourfold rise of AST (>=160 IU/l) was taken to 
indicate reactivation of disease and if this occurred, 
Thymostimulin was discontinued and treatment 
recommenced with prednisolone (30 mg) and 
azathioprine (75 mg).

**SUPPRESSOR CELL ASSAY**

The assay used to examine suppressor T cell 
function has been previously described9 and is based 
on the ability of concanavalin A (con A) stimulated 
suppressor cells to inhibit B cell proliferation and 
immunoglobulin production. Briefly, peripheral 
blood lymphocytes were isolated9 and cultured with 
pokeweed mitogen, a B cell stimulant, in the 
presence or absence of con A, for seven days in an 
atmosphere of 5% CO2 in air. The number of 
stimulated B cells secreting immunoglobulin G 
(IgG) in the presence and absence of con A 
activated suppressor cells was then determined by 
means of haemolytic plaque assay. In this assay 
secreted immunoglobulins bind to staphylococcus 
protein A coated sheep red blood cells. When anti-IgG 
and complement are added lysis of the red 
cells occurs, producing clear areas in an agar gel 
around each immunoglobulin secreting cell. Each 
study was performed in duplicate and the number of 
haemolytic plaques reported per 10⁶ viable cells as 
assessed by trypan blue exclusion. The results are 
expressed as % suppression (suppression index) 
based on the ratio of the number of immunoglobulin 
secreting cells in the presence and absence of con A 
activated suppressor cells. The following formula 
was used:

\[
% \text{ suppression (suppression index)} = 1 - \frac{\text{No of IgG producing cells (pokeweed mitogen + con A)}}{\text{No of IgG producing cells (pokeweed mitogen)}} \times 100
\]

**Results**

**CLINICAL** (Fig. 1)

Reactivation of disease occurred in 11 out of 13 
Thymostimulin treated patients (84%) compared 
with 14 out of 17 (82%) of patients receiving no 
therapy (p>0.05, \( \chi^2 \) analysis) (Fig. 1) and was 
confirmed histologically by the presence of 
piecmeal necrosis in all 13 patients (seven Thymo-
stimulin treated; six untreated) where liver biopsy 
was performed. The mean interval between 
withdrawal of treatment and reactivation of disease 
was similar in the Thymostimulin and untreated

![Fig. 1](http://gut.bmj.com/)

**Fig. 1** **Chronic active hepatitis. Percentage of patients with** relapse of disease following treatment withdrawal. (—) and (-----) represent percentage relapse in patients who did and did not receive Thymostimulin.
groups (9-3 and 11-2 weeks respectively) as was the mean increase in AST (581 and 600 U/l) and rise of serum IgG (20-1 and 20-5 g/l). Changes in serum autoantibody titres or the reappearance of autoantibodies in patients who had become autoantibody negative on corticosteroid treatment was similar in the two groups.

Suppressor cell function (Fig. 2)
Suppressor cell function was studied before treatment withdrawal in 15 patients with inactive disease maintained on prednisolone and azathioprine and in the same group of patients after reactivation of disease. Seven of these patients received Thymostimulin from the start of treatment withdrawal. Twenty normal laboratory volunteers (aged 19–63 years) served as controls. Before withdrawal of treatment the suppression index in the patients with inactive disease (78-3 ± SD 10-8) was similar to control values (84-4 ± SD 10-4 p>0-05; Wilcoxon’s rank sum test) and did not differ between those patients who did (79-6 ± SD 13-1) and did not (77-6 ± SD 18-9) receive Thymostimulin. A defect in suppressor cell function accompanied reactivation of disease in all patients studied, the magnitude of which was similar in the Thymostimulin treated (16-4 ± SD 38-2) and untreated (3-2 ± SD 32-4 p>0-05) groups.

Discussion
Thymic hormone extracts induce differentiation of murine and human thymus dependent T lymphocytes as assessed by expression of specific surface markers, formation of spontaneous erythrocyte rosettes, graft vs host reactivity and sensitivity to T cell specific antisera, azathioprine, or hydrocortisone. In addition, thymic extracts have been shown to inhibit the proliferative response of normal human lymphocytes to mitogens and to reverse a suppressor cell defect in systemic lupus erythematosus by mediating the differentiation of precursor T cells to functional suppressor cells. The potential therapeutic importance of these in vitro observations has been emphasised by the results of studies in which administration of thymic extracts has abolished immunoregulatory abnormalities and induced clinical remission in patients with histiocytosis X (a disease characterised by defective suppressor T cell function) and other immune deficiency states. These data suggested that thymic extracts might also be of benefit in autoimmune chronic active hepatitis, a disease in which defective suppressor T cell function is thought to play a major pathogenic role.

The present study confirms previous observations that reactivation of disease accompanied by a defect in suppressor cell function occurs in the majority of patients with autoimmune chronic active hepatitis when maintenance corticosteroid treatment is withdrawn. Thymostimulin, at the dose used, had no effect on the clinical course or on the appearance of the suppressor cell abnormality during treatment withdrawal. Reactivation of disease occurred as often in the Thymostimulin treated and untreated groups and was invariably accompanied by a defect in suppressor cell function, the magnitude of which was similar in the two groups. There are a number of possible explanations for this apparent lack of an effect of Thymostimulin in this study. Many of the in vitro studies showing an immunomodulatory effect of thymic extracts used a concentration which would far exceed the anticipated plasma levels in patients receiving the regime used in the present study. This problem should be at least partially resolved with the recent development of a sensitive immunoassay for serum thymic hormone levels which may allow evaluation of the immunological effects of Thymostimulin at comparable concentrations in vivo and in vitro. Previous studies had shown that, in some patients, there was a latent period of up to six months between initial administration of Thymostimulin and maximal improvement in T cell maturation and parameters of delayed hypersensitivity. If indeed a prolonged period of treatment is required to produce an immunological response, the lack of an effect of Thymostimulin in the present study may be because the duration of
treatment was not long enough to allow maturation of immunocompetent suppressor T cells.

Thymic extracts have been shown in vitro to stimulate both helper and suppressor T cell activity in an unpredictable fashion. As the suppressor cell assay used in the present study measures the net effect of suppressor and helper T cells on B cell immunoglobulin production, it is not possible to categorically state that Thymostimulin is not stimulating suppressor cells as simultaneous stimulation of helper T cells would result in an apparent lack of effect on suppressor cells. Stimulation of both suppressor and helper cells by thymic extracts may have important clinical implications. The autoimmune process in chronic active hepatitis may be primarily due to defective suppressor cell function resulting in uncontrolled proliferation of B cells which produce tissue damaging autoantibodies. In these circumstances preferential stimulation of helper T cells could theoretically aggravate rather than ameliorate the immunological abnormalities and produce clinical deterioration.

These results represent the first controlled study on the effect of long term parenteral administration of a thymic hormone extract in a well defined, homogenous, carefully monitored patient population. The lack of a demonstrable clinical and immunological effect contrasts with the results of previous in vivo and in vitro studies suggesting that further evaluation is required to assess the effect of different dose schedules, and modes of administration of thymic extracts in patients with chronic active hepatitis.

References

22 Hegarty JE, Nouri Aria KT, Eddleston ALWF,


Controlled trial of a thymic hormone extract (Thymostimulin) in 'autoimmune' chronic active hepatitis.
J E Hegarty, K T Nouri Aria, A L Eddleston and R Williams

Gut 1984 25: 279-283
doi: 10.1136/gut.25.3.279

Updated information and services can be found at:
http://gut.bmj.com/content/25/3/279

Email alerting service
These include:
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/